What We Learned From Q1 Pharma Earnings Season
Understand key dynamics and trends in this Scrip webinar
Executive Summary
With US drug pricing pressures and generic and biosimilar competition weighing on big pharma, new launches and brisk business in China have been providing a silver lining. Scrip writers analyze the industry landscape in light of the first-quarter results.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.